

Please amend the subject application as follows:

In the Specification

On page 9, line 9, delete "innunodeficiency" and substitute --immunodeficiency-- therefor.

On page 10, line 3, delete "supranucleo" and substitute --supranuclear-- therefor.

On page 10, line 9, delete "abetalipoproteemia" and substitute --abetalipoproteinemia-- therefor.

On page 10, line 21, delete "Hallerrorden" and substitute --Hallervorden-- therefore.

On page 14, line 11, delete "1994)," insert [ ] 1994, now US Patent No. 5,656,272), --/therefor.

On page 22, line 16, delete "Chimeric".

On page 22, delete lines 17-20.

On page 35, line 14, delete "Rheumatrex®" and substitute --RHEUMATREX®-- therefor.

In the Claims

Please cancel Claim 4 and amend Claims 1-3 and 5-31 as follows:

- Q2 cont'd  
Sub  
ID'
1. (Amended) A method [for] of treating [or preventing a tumor necrosis factor-mediated] an autoimmune or inflammatory disease in an individual in need thereof comprising co-administering methotrexate and an anti-tumor necrosis factor alpha antibody or antigen-binding fragment thereof to the individual, in therapeutically effective amounts.
  2. (Amended) A method of Claim 1 wherein the anti-tumor necrosis factor alpha antibody and methotrexate are administered simultaneously.